Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome

Development and validation of a questionnaire to measure asthma control

Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473

The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome (allergic granulomatosis and angiitis)

Masi, A. T., Hunder, G. G., Lie, J. T., Michel, B. A., Bloch, D. A., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330806 · Cited by 2,212

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W. R., Sousa, A. R., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,873

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response

Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A., Cowley, H., Chung, K. F., Djukanović, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,810

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

Nair, P. K., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O’Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,346

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056

Interleukin-5, eosinophils, and disease

Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.bloodjournal79123101 · Cited by 972

Interleukin-5, eosinophils, and disease

Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.3101 · Cited by 860

Eosinophil's Role Remains Uncertain as Anti–Interleukin-5 only Partially Depletes Numbers in Asthmatic Airway

Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808

A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma

Flood-Page, P. T., Swenson, C. A., Faiferman, I., Matthews, J. G., Williams, M. J. A., Brannick, L., Robinson, D. S., Wenzel, S. E., Busse, W. W., Hansel, T. T., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-085oc · Cited by 750

Current Therapies for ANCA-Associated Vasculitis

Lally, L., & Spiera, R. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-011514-023051 · Cited by 26

Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: Eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome?

Lefèvre, G., Ackermann, F., & Kahn, J. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.11.001 · Cited by 26

Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis

Garcés, R. R., Prieto‐González, S., Hernández‐Rodríguez, J., Arismendi, E., Alobid, I., Penatti, A. E., Cid, M. C., & Espígol‐Frigolé, G. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.08.021 · Cited by 25

Therapeutic Strategies for Harnessing Human Eosinophils in Allergic Inflammation, Hypereosinophilic Disorders, and Cancer

Amini, Z., Martinez-Moczygemba, M., & Huston, D. P. (2012) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0290-3 · Cited by 25

Biologics for severe asthma and beyond

Mümmler, C., & Milger, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108551 · Cited by 25

IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome

Rosenwasser, L. J., & Rothenberg, M. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.022 · Cited by 24

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma

Haldar, P. (2017) · Biologics · doi:10.2147/btt.s93954 · Cited by 23

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

Kampylafka, E. I., Alexopoulos, H., Dalakas, M. C., & Tzioufas, A. G. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0393-3 · Cited by 23

Future treatment for asthma

Charriot, J., Vachier, I., Halimi, L., Gamez, A. S., Boissin, C., Salama, M., Cucu-Jarjour, A., Ahmed, E., & BOURDIN, A. A. (2016) · European Respiratory Review · doi:10.1183/16000617.0069-2015 · Cited by 25

Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis

Furuta, S., & Jayne, D. R. W. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000005 · Cited by 22

Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential

Menzella, F., Lusuardi, M., Galeone, C., Taddei, S., Facciolongo, N. C., & Zucchi, L. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316659863 · Cited by 22

Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

Pagnoux, C., & Groh, M. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1191352 · Cited by 22

Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort Study

Seeliger, B., Förster, M., Happe, J., Forberg, T., Moeser, A., Neumann, T. E., & Kroegel, C. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.160907 · Cited by 21

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab

Menzella, F., Galeone, C., Ghidoni, G., Ruggiero, P., Capobelli, S., Simonazzi, A., Catellani, C., Scelfo, C., Livrieri, F., & Facciolongo, N. C. (2021) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2021.779 · Cited by 21

An update on emerging drugs for asthma

Walsh, G. M. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.657625 · Cited by 22

Role of Cytokines in EGPA and the Possibility of Treatment with an Anti-IL-5 Antibody

Isozaki, T., Homma, T., Sagara, H., & Kasama, T. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123890 · Cited by 21

Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population

Chen, Y., Guo, X., Zhou, J., Li, J., Wu, Q., Yang, H., Zhang, S., Fei, Y., Zhang, W., Zhao, Y., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.583944 · Cited by 21

Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies

Menditto, V. G., Rossetti, G., Olivari, D., Angeletti, A., Rocchi, M., Gabrielli, A., & Pomponio, G. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab046 · Cited by 20

A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis

Koike, H., Nishi, R., Yagi, S., Furukawa, S., Fukami, Y., Iijima, M., & Katsuno, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02307-x · Cited by 20

Biological drugs in ANCA-associated vasculitis

Lutalo, P., & D’Cruz, D. P. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.04.023 · Cited by 20

Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies

Navarro-Mendoza, E., & Tobón, G. J. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0736-2 · Cited by 20

Autoimmune neuropathies associated to rheumatic diseases

Martínez, A., Faber, I., Nucci, A., Appenzeller, S., & França, M. C. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.02.003 · Cited by 19

Cutaneous Manifestations of Reactions to Biologics

Otani, I. M., Levin, A. S., & Banerji, A. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0764-z · Cited by 19

Update on the treatment of ANCA associated vasculitis

Smith, R. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.04.008 · Cited by 17

Therapeutic immunomodulation in systemic vasculitis: Taking stock

Puéchal, X., & Guillevin, L. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.10.023 · Cited by 17

Incidence, Prevalence, and Mortality of Eosinophilic Granulomatosis With Polyangiitis in Korea: A Nationwide Population-Based Study

Lee, J.-H., Hong, S. H., Yu, I., Chang, M.-S., Park, S., Lee, S. J., & Kim, S. (2024) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2024.16.2.168 · Cited by 16

Biological Modulators in Eosinophilic Diseases

Sriaroon, P., & Ballow, M. C. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8444-9 · Cited by 16

Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn

Cornec, D., Gall, É. C.-L., & Specks, U. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw384 · Cited by 16

Biology of Eosinophils

Kita, H., & Bochner, B. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-323-08593-9.00017-6 · Cited by 16

Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?

Vergles, M., Matković, Z., Lalić, K., Tekavec-Trkanjec, J., & Tudorić, N. (2020) · Journal of Asthma · doi:10.1080/02770903.2020.1827417 · Cited by 16

Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis

Uzzo, M., Regola, F., Trezzi, B., Toniati, P., Franceschini, F., & Sinico, R. A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.754434 · Cited by 16

Advances in the diagnosis and treatment of eosinophilia

Helbig, G. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000011 · Cited by 16

Retiform purpura: Workup and therapeutic considerations in select conditions

Georgesen, C., Fox, L. P., & HARP, J. L. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.113 · Cited by 16

Mepolizumab treatment for asthma

Robinson, D. S. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.725717 · Cited by 15

Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis

Ennis, D., Lee, J. K., & Pagnoux, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1623875 · Cited by 15

Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes

Santos, Y. A. P., Silva, B. R. A., Lira, P. N. Z. B. A., Vaz, L. C. A., Mafort, T. T., Bruno, L. P., & Lopes, A. J. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.03.006 · Cited by 15

A drug safety review of treating eosinophilic asthma with monoclonal antibodies

Mitchell, P., & Leigh, R. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1675634 · Cited by 15

Eosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss syndrome): where are we now?

Groh, M., Pagnoux, C., & Guillevin, L. (2015) · European Respiratory Journal · doi:10.1183/13993003.00963-2015 · Cited by 15

Biologic Therapy and Asthma

Viswanathan, R. K., & Busse, W. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1606218 · Cited by 14

Targeted immunotherapy strategies in ANCA-associated vasculitis

Puéchal, X. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.09.002 · Cited by 14

Lessons learned from targeting eosinophils in human disease

Kuang, F. L., & Bochner, B. S. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00849-w · Cited by 14

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Masumoto, N., Oshikata, C., Nakadegawa, R., Motobayashi, Y., Osada, R., Manabe, S., Kaneko, T., & Tsurikisawa, N. (2023) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-023-00801-7 · Cited by 13

Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study

Ishii, T., Kunishige, H., Kobayashi, T., Hayashi, E., Komatsubara, M., Alfonso-Cristancho, R., Tamaoki, J., & Howarth, P. H. (2024) · Modern Rheumatology · doi:10.1093/mr/roae100 · Cited by 13

IgG4-related Disease: 2013 Update

Monach, P. A. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0232-y · Cited by 13

Eosinophilic granulomatosis with polyangiitis

Nanzer, A. M., & Wechsler, M. E. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10029820 · Cited by 12

Management of Small Vessel Vasculitides

Lopalco, G., Rigante, D., Venerito, V., Emmi, G., Anelli, M. G., Lapadula, G., Iannone, F., & Cantarini, L. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0580-1 · Cited by 12

Anti-cytokine targeted therapies for ANCA-associated vasculitis

Bała, M. M., Malecka-Massalska, T. J., Koperny, M., Zając, J., Jarczewski, J. D., & Szczeklik, W. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008333.pub2 · Cited by 12

Churg–Strauss syndrome: Case series

Alfaro, T. M., Duarte, C. C. M., Monteiro, R. L., Simão, A., Calretas, S., & Costa, N. (2012) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2012.01.005 · Cited by 11

ANCA-Associated Vasculitis

Hazebroek, M. R., van Paassen, P., Dennert, R. M., & Heymans, S. R. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803267-1.00020-x · Cited by 11

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis

Pradhan, R. R., Nepal, G., & Mandal, S. (2019) · Pulmonary Medicine · doi:10.1155/2019/4376380 · Cited by 11

Leukotriene Inhibitors in Sinusitis

Steinke, J. W., & Kennedy, J. L. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0245-9 · Cited by 11

Multisystem diseases affecting the skin and eye

Wanat, K. A., Kim, B. B., & Rosenbach, M. A. (2015) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2015.11.013 · Cited by 11

Advances in adult asthma diagnosis and treatment and HEDQ in 2010

Apter, A. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.017 · Cited by 11

Cellular Immunology of Myocarditis: Lights and Shades—A Literature Review

Vicenzetto, C., Giordani, A. S., Menghi, C., Baritussio, A., Scognamiglio, F., Pontara, E., Bison, E., Cattini, M. G., Marcolongo, R., & Caforio, A. L. P. (2024) · Cells · doi:10.3390/cells13242082 · Cited by 12

Anti-IL5/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated Systematic Review

Lazzeroni, M., Longoni, V., Schiavo, P., Bizzi, E., Brucato, A. L., Gramellini, G., Borin, M., Dragonetti, A. G., Gaffuri, M., Lentini, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1587158 · Cited by 10

Síndrome de Churg-Strauss: casuística

Alfaro, T. M., Duarte, C. C. M., Monteiro, R. L., Simão, A., Calretas, S., & Costa, N. (2012) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppneu.2011.12.001 · Cited by 10

Update on systemic vasculitides

Anwar, S., & Karim, M. Y. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203875 · Cited by 10

Advances in the pharmacotherapeutic management of eosinophilic granulomatosis with polyangiitis

Pagnoux, C., & Berti, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2216379 · Cited by 10

Eosinophilic granulomatosis with polyangitis: A new target for biologicals

Durmaz, M. S. B., Sözener, Z. Ç., & Bavbek, S. (2022) · Tuberkuloz ve Toraks · doi:10.5578/tt.20229911 · Cited by 9

Physiology and pathology of eosinophils: Recent developments

Renz, H. E., Bachert, C., Berek, C., Hamelmann, E. H., Levi‐Schaffer, F., Raap, U., Simon, H., Ploetz, S. G., Taube, C., Valent, P., et al. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13032 · Cited by 9

Leukocytoclastic Vasculitis

Dvoryankova, E. V., Nevozinskaya, Z. A., Sakaniya, L. R., & Korsunskaya, I. M. (2019) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2019-15-35-20-24 · Cited by 9

Biologic Therapies for Immunoglobulin E–mediated Food Allergy and Eosinophilic Esophagitis

Otani, I. M., & Nadeau, K. C. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.01.010 · Cited by 9

Churg-Strauss Syndrome or Eosinophilic Granulomatosis with Polyangiitis

Izquierdo-Domínguez, A., Cordero Castillo, A., Alobid, I., & Mullol, J. (2015) · Sinusitis · doi:10.3390/sinusitis1010024 · Cited by 8

Clinico-radiological correlation and prognostic value of baseline chest computed tomography in eosinophilic granulomatosis with polyangiitis

Delestre, F., Brun, A., Thoreau, B., Taillé, C., Limal, N., Puéchal, X., Mouthon, L., Guillevin, L., Revel, M., & Terrier, B. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead077 · Cited by 8

Comment traiter une vascularite nécrosante ?

Guillevin, L. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.06.008 · Cited by 8

Antineutrophil Cytoplasmic Antibody Associated Vasculitis

Cabral, D. A., & Morishita, K. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24145-8.00036-3 · Cited by 8

Anti-neutrophil Cytoplasmic Antibody–Associated Vasculitis

Chung, S. A., & Monach, P. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00089-9 · Cited by 8

New-generation therapy for ANCA-associated vasculitis

Jayne, D. R. W. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0855-z · Cited by 8

Biologics for ANCA-Associated Vasculitis

Murgia, G., Firinu, D., Manconi, P. E., & Giacco, S. R. D. (2014) · Inflammation & Allergy - Drug Targets · doi:10.2174/1871528113666140702094456 · Cited by 7

Sinusitis, Rhinitis, Asthma, and the Single Airway Hypothesis

Chang, C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0265-1_11 · Cited by 9

Antineutrophil cytoplasmic antibody–associated vasculitis

Unizony, S. H., & Stone, J. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00157-1 · Cited by 7

Treatment of ANCA-Associated Vasculitides

Guillevin, L. (2016) · Springer eBooks · doi:10.1007/978-3-319-40136-2_35 · Cited by 7

Update on targeted treatments for ANCA-associated vasculitis

Puéchal, X. (2024) · Joint Bone Spine · doi:10.1016/j.jbspin.2024.105768 · Cited by 6

Ear, nose, and throat involvement in eosinophilic granulomatosis with polyangiitis

Baldwin, C., Wolter, N. E., & Pagnoux, C. (2015) · Advances in Cellular and Molecular Otolaryngology · doi:10.3402/acmo.v3.27181 · Cited by 6

Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities

Khoury, P., Roufosse, F. E., Kuang, F. L., Ackerman, S. J., Akuthota, P., Bochner, B. S., Johansson, M. W., Mathur, S. K., Ogbogu, P. U., Spencer, L. A., et al. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae051 · Cited by 6

Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship

Cao, M., Hermida, T. F., Leite, B. N., Gutiérrez, F. P., Bolaños, L., Valdés, F., Alonso, Á., Vázquez, E., Mosquera, J. M., Trigás-Ferrín, M., et al. (2017) · CEN Case Reports · doi:10.1007/s13730-017-0251-8 · Cited by 6

An alternative approach against eosinophils for the treatment of eosinophilic granulomatosis with polyangiitis

Carrillo‐Martin, I., Abril, A., Donaldson, A. M., & Gonzalez‐Estrada, A. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.01.037 · Cited by 6

Vasculitis: From Target Molecules to Novel Therapeutic Approaches

Chung, S. W. (2021) · Biomedicines · doi:10.3390/biomedicines9070757 · Cited by 6

Aktuelle Therapie der eosinophilen Granulomatose mit Polyangiitis (Churg-Strauss-Syndrom)

Moosig, F., & Holle, J. U. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-018-0580-9 · Cited by 6

Churg–Strauss Syndrome with Eosinophilic Myocarditis

Levine, A. B., Kalliolias, G. D., Heaney, M. L., Endo, Y., Gersten, A., Weinsaft, J. W., Spiera, R., Bass, A. R., & Erkan, D. (2012) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-012-9276-x · Cited by 6

Three cases of relapsed eosinophilic sinusitis without eosinophilia during mepolizumab maintenance therapy for eosinophilic granulomatosis with polyangiitis

Nishisaka, K., Ueda, Y., Inoue, M., Ishikawa, M., Kageyama, G., & Saegusa, J. (2024) · Clinical Rheumatology · doi:10.1007/s10067-024-07133-w · Cited by 5

A current review on animal models of anti-asthmatic drugs screening

Singh, S. K., Kularia, S., Shukla, S., Singh, M., Kumar, M., & Sharma, A. K. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1508460 · Cited by 6

Hyperéosinophilies et syndromes hyperéosinophiliques

Kahn, J., Legrand, F., Capron, M., & Prin, L. (2011) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/s1155-1984(11)52510-5 · Cited by 5

Investigational drugs in systemic vasculitis

Mirouse, A., Cacoub, P., Desbois, A. C., Comarmond, C., Pagnoux, C., & Saadoun, D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1361928 · Cited by 5

Current and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis

Berti, A., Specks, U., Keogh, K. A., & Cornec, D. (2017) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-017-0073-z · Cited by 5

Tailored therapy for severe asthma

Menzella, F., Lusuardi, M., Galeone, C., & Zucchi, L. (2015) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2015.275 · Cited by 5

Biologics in vasculitides: Where do we stand, where do we go from now?

Pazzola, G., Muratore, F., Pipitone, N., & Salvarani, C. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.04.010 · Cited by 5

Therapeutic immunomodulation in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Puéchal, X. (2015) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.05.007 · Cited by 5

Granulocytes: Neutrophils, Basophils, Eosinophils

Bosch, X., & Ramos‐Casals, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00013-0 · Cited by 5

INTERLEUKIN-5 IS A NEW TARGET IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Beketova, T. V., & Arseniev, E. V. (2020) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2020-321-329 · Cited by 5

Steroid alternatives for managing eosinophilic lung diseases

Delcros, Q., Groh, M., Nasser, M., Kahn, J., & Cottin, V. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.2003777 · Cited by 5

Eosinophile Granulomatose mit Polyangiitis

Hellmich, B., Holle, J. U., & Moosig, F. (2022) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01153-6 · Cited by 5

Anti-cytokine targeted therapies for ANCA-associated vasculitis

Bała, M. M., Malecka-Massalska, T. J., Koperny, M., Zając, J., & Szczeklik, W. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008333 · Cited by 5

Churg-Strauss syndrome with necrosis of toe tips.

Waseda, K., Tanimoto, Y., Hasegawa, K., Miyahara, N., Nojima, D., Ikeda, G., Kanehiro, A., Okada, C., Kimata, Y., & Tanimoto, M. (2011) · PubMed · doi:10.18926/amo/46635 · Cited by 5

L6. Eosinophilic granulomatosis with polyangiitis: Future therapies

Moosig, F. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.01.006 · Cited by 5

Eosinophilic granulomatosis with polyangiitis: Patient profiles from a large US allergy practice

Wechsler, M. E., Kovalszki, A., Silver, J. N., Stone, B. D., McCann, W., Huynh, L. Y., Khanal, A., Ye, M., Duh, M. S., & Deb, A. (2025) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2025.100437 · Cited by 4

Superiority of Avacopan and Mepolizumab to Glucocorticoid Tapering in the Treatment of Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review

Gattu, R., Beckler, M. D., & Kesselman, M. M. (2024) · Cureus · doi:10.7759/cureus.67161 · Cited by 4

New therapeutic approaches for ANCA-associated vasculitides

Chaigne, B., & Guillevin, L. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.05.003 · Cited by 4

Current approaches to diagnosing and treating eosinophilic granulomatosis with polyangiitis: The 2015 international guidelines

Beketova, T. V., Volkov, M., & Насонов, Е. Л. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh201688586-92 · Cited by 4

Perspectives de traitement par biomédicaments dans la granulomatose éosinophilique avec polyangéite (Churg-Strauss)

Puéchal, X. (2017) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2017.03.005 · Cited by 4

Mepolizumab as a Steroid-Sparing Treatment in the Churg Strauss Syndrome.

Sh, K., Israel, E., Oren, E., & Wechsler, M. E. (2009) · doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5468 · Cited by 2

Oral glucocorticoid-sparing effects of mepolizumab. A real-life study.

Bjerrum, A., Schmid, J., & Skjold, T. (2018) · doi:10.1183/13993003.congress-2018.pa601 · Cited by 2

Efficacy and safety of mepolizumab in eosinophilic granulomatosis with polyangiitis: Insights from real-life cases and literature analysis.

Cassone, G., Sebastiani, M., Cataleta, P., Olivi, E., Gurioli, C., Cerri, S., Beghé, B., Giuggioli, D., & Manfredi, A. (2025) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v42i1.16311 · Cited by 1

Rationale and design of a placebo-controlled trial to evaluate the steroid-sparing effects of anti-IL5 monoclonal antibody (mepolizumab): Focus on cutaneous outcomes in patients with hypereosinophilic syndrome (HES)

(2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.10.347

Late-breaking abstract: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: The SIRIUS study

Bel, E. H., Wenzel, S., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S., Ortega, H., & Pavord, I. D. (2014) · European Respiratory Journal · doi:10.1183/13993003/erj.44.suppl_58.2907 · Cited by 10